about
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsPeripheral artery disease: current insight into the disease and its diagnosis and management.Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysisA review of the role of anticoagulation in the treatment of peripheral arterial disease.The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.Novel treatments for cardiovascular disease prevention.Proton pump inhibitor and clopidogrel interaction: fact or fiction?Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.Peripheral artery disease. Part 2: medical and endovascular treatment.Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.The evolution of antiplatelet therapy in cardiovascular disease.Antiplatelet agents for the treatment and prevention of atherothrombosis.Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.Antiplatelets in acute coronary syndrome: personal perspectives.Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.P2 receptors and platelet function.Antiplatelet drugs: which targets for which treatments?Major themes for 2009 in cardiothoracic and vascular anesthesia.Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention.P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen.Perioperative management of the bleeding patient.
P2860
Q26861200-7CBCA7BD-2D1C-483E-9202-381725A3943EQ33951581-4C611D60-AC13-4DDC-8D66-9573E6B7C1ADQ34994015-DCA0A7B2-4AD8-44CA-93DF-88981861DDC2Q35089550-01242ED1-76B0-402A-9227-8DF9350C65E0Q36337254-CA92E101-6C04-4EC3-9480-1AA35516D9AAQ36627535-E3F6F98F-BDF3-48F4-AD85-5B7F71D08B94Q37194881-A363509C-9B55-493E-9268-1EF1B9F652A0Q37548399-AFC39B0E-C922-44C3-9F05-F3C2B935AC2FQ37630911-66068B45-30B5-467F-A6DD-27C19665EF9EQ37841560-BF7EBEE4-B86E-43DF-9948-641BE3F46F9EQ37889106-8C293DF6-0533-4323-8EE9-B9229D1A5A61Q37897674-12CA286E-DEB6-41B4-9F1C-88CD03C16E96Q37900470-810E469F-4579-4914-AE8A-9AA875069387Q37948506-B05569B7-3C36-4B3F-AA19-FCF7DFCCD3E6Q38008828-A7ADAEDC-BFCF-4D1E-8FC4-D3D924305607Q38068595-D6C51055-7322-437B-AE2E-3F181C11A26EQ38243032-13095BE8-1F1E-447B-AF49-96A063E49EBAQ38306634-FA59F940-BAFA-4BAA-8A92-0A6FFC2FBED2Q38543308-9B19EF95-B67C-48F5-8DE3-B44B20A5E37DQ39913995-642F5870-314A-440E-B698-AAFC0E97D235Q41250240-75DFE1B6-ED35-4311-981F-BE425F4DF2CAQ41511099-DB21907C-89B3-431D-A2FB-C831DA6EF8B7Q43182489-A334D284-234D-47B3-91B0-CEE5181C8FD0Q43222630-B37FC69C-64C6-4959-994E-892E2ED4B80EQ50312912-A9057903-92A3-4B68-87A0-22AC999DC626
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Prasugrel in clinical practice.
@en
Prasugrel in clinical practice.
@nl
type
label
Prasugrel in clinical practice.
@en
Prasugrel in clinical practice.
@nl
prefLabel
Prasugrel in clinical practice.
@en
Prasugrel in clinical practice.
@nl
P356
P1476
Prasugrel in clinical practice.
@en
P2093
Deepak L Bhatt
P304
P356
10.1056/NEJMP0806848
P407
P577
2009-07-15T00:00:00Z